Compare McKesson Corporation (MCK) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? McKesson Corporation trades at $828.03 (market cap $97.35B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.13. The key difference: McKesson Corporation pays a 0.39% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and McKesson Corporation is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| MCK | YINN | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $56.62 |
52-Week Low | $659.01 | $21.45 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $28.89, up 7.84% with a bullish technical signal. The leveraged ETF structure amplifies exposure to Chinese equities, which face mixed sentiment amid economic stabilization efforts and US-China tensions. Moving averages show bullish momentum while oscillators remain neutral, with key resistance at $27.
Outlook remains volatile given YINN's 3x leverage structure and China's economic crosscurrents. Investment opportunity exists for tactical traders betting on China's infrastructure and AI stimulus, but risks include geopolitical friction and leveraged decay. The fund's performance hinges on Beijing's policy effectiveness versus US restrictions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
